Tenaya Therapeutics Inc. Stock Price, News, Quote & History

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Tenaya Therapeutics Inc.

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

5 US Longevity and Anti-aging Stocks to Watch in 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I Populations

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Canacol Energy Ltd Provides Information on Arbitration Process

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Latest News

Outlook Reports world

Featured Biotech Investing Stocks

Browse Companies